JSAM
COGT icon

J. Safra Asset Management’s Cogent Biosciences COGT Stock Holding History

J. Safra Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Sell
695
-94
-12% -$3.29K ﹤0.01% 300
2026
Q1 		$30.4K Buy
789
+534
+209% +$19.7K ﹤0.01% 285
2025
Q4 		$9.06K Sell
255
-11
-4% -$309 ﹤0.01% 369
2025
Q3 		$3.82K Hold
266
– – ﹤0.01% 329
2025
Q2 		$1.91K Hold
266
– – ﹤0.01% 350
2025
Q1 		$1.59K Buy
+266
New +$2.09K ﹤0.01% 329

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

J. Safra Asset Management's COGT Position: Q2 2026 in Review

J. Safra Asset Management reduced its Cogent Biosciences (COGT) stake by 12% in Q2 2026, selling an estimated $3.29K and leaving 695 shares worth $26.9K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

J. Safra Asset Management first reported a position in COGT in Q1 2025 and has held it in 6 quarters since. The position peaked at $30.4K in Q1 2026. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • J. Safra Asset Management held 695 shares of Cogent Biosciences worth $26.9K as of Q2 2026.
  • J. Safra Asset Management sold 94 Cogent Biosciences shares in Q2 2026, an estimated $3.29K.
  • Cogent Biosciences made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #300 holding.
  • J. Safra Asset Management first reported a position in Cogent Biosciences in Q1 2025 and has held it in 6 quarters since.
  • J. Safra Asset Management's Cogent Biosciences position peaked at $30.4K in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.